Does Rallies show 13F holders for PRME?

Yes. Rallies tracks hedge fund and 13F ownership data for PRME, including fund names, share counts, latest tracked quarter, and position changes when available.

Is PRME research on Rallies investment advice?

No. Rallies provides research, data, and educational context for PRME. It does not provide personalized investment advice.

PRME (Prime Medicine, Inc. Common Stock) Stock Analysis - Hedge Fund Holdings

Prime Medicine, Inc. Common Stock (PRME) is a publicly traded Healthcare sector company. As of May 21, 2026, PRME trades at $2.81 with a market cap of $507.54M and a P/E ratio of -2.08. PRME moved +0.00% today. Year to date, PRME is -20.73%; over the trailing twelve months it is +140.85%. Its 52-week range spans $1.11 to $6.94. Analyst consensus is strong buy with an average price target of $7.80. Rallies surfaces PRME's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns PRME stock?

Hedge funds tracked by Rallies that own PRME include Redmile Group, Farallon Capital, and Sculptor Capital. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Prime Medicine, Inc. Common Stock.

PRME Key Metrics

Key financial metrics for PRME
Metric	Value
Price	$2.81
Market Cap	$507.54M
P/E Ratio	-2.08
EPS	$-1.35
Dividend Yield	0.80%
52-Week High	$6.94
52-Week Low	$1.11
Volume	79.85K
Avg Volume	0
Revenue (TTM)	$4.63M
Net Income	$-201.14M
Gross Margin	0.00%

Top Hedge Funds Holding PRME

Redmile Group holds 1.59M shares of PRME, changed +1726.07% as of Mar 31, 2026.
Farallon Capital holds 1.24M shares of PRME, changed +0.00% as of Mar 31, 2026.
Sculptor Capital holds 50.70K shares of PRME, changed +0.00% as of Dec 31, 2024.

Latest PRME News

Prime Medicine Secures $149.2M Cash Into 2027, Eyes Two IND Filings — May 7, 2026
Prime Medicine Appoints Svetlana Makhni as CFO Ahead of Wilson Disease and AATD Clinical Trials — Apr 16, 2026
Prime Medicine's Prime Editing Platform Targets Scalable Cell Manufacturing in $578B Market — Apr 1, 2026
Prime Medicine’s Prime Editing Platform Cuts Off-Target Risks Without Double-Strand Breaks — Mar 24, 2026
Prime Medicine Secures $191.4M Cash Runway, Targets Wilson Disease IND in H1 2026 — Mar 8, 2026

Recent PRME Insider Trades

GV 2021 GP, L.L.C. bought 1.50M (~$4.95M) on Aug 1, 2025.
NELSEN ROBERT bought 3.03M (~$10.00M) on Aug 1, 2025.
ARCH Venture Partners XII, LLC bought 3.03M (~$10.00M) on Aug 1, 2025.

PRME Analyst Consensus

8 analysts cover PRME: 0 strong buy, 6 buy, 2 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $7.80.

Common questions about PRME

Who owns PRME stock?: Hedge funds tracked by Rallies that own PRME include Redmile Group, Farallon Capital, and Sculptor Capital. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Prime Medicine, Inc. Common Stock.
Does Rallies show 13F holders for PRME?: Yes. Rallies tracks hedge fund and 13F ownership data for PRME, including fund names, share counts, latest tracked quarter, and position changes when available.
Is PRME research on Rallies investment advice?: No. Rallies provides research, data, and educational context for PRME. It does not provide personalized investment advice.